CLAIMS

1. A polypeptide comprising a heavy chain CDR3 (HCDR3) having an amino acid sequence as set forth in SEQ ID NO: 4; or having at least 70% sequence identity thereto.

2. The polypeptide according to claim 1, wherein the polypeptide comprises a heavy chain CDR1 (HCDR1) having an amino acid sequence as set forth in SEQ ID NO: 2, a heavy chain CDR2 (HCDR2) having an amino acid sequence as set forth in SEQ ID NO: 3, and a heavy chain CDR3 (HCDR3) having an amino acid sequence as set forth in SEQ ID NO: 4; or having at least 70% sequence identity to said HCDR3.

3. The polypeptide according to claim 1 or 2, wherein the polypeptide comprises a heavy chain CDR1 (HCDR1) having an amino acid sequence as set forth in SEQ ID NO: 2, a heavy chain CDR2 (HCDR2) having an amino acid sequence as set forth in SEQ ID NO: 3, and a heavy chain CDR3 (HCDR3) having an amino acid sequence as set forth in SEQ ID NO: 4,

wherein each of the HCDRs may contain one, two, or at most three amino acid variations.

4. The polypeptide according to any one of claims 1-3, wherein the polypeptide comprises a heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO: 1, or having at least 80%, or at least 85%, or at least 90%, or at least 95%, sequence identity thereto.

5. The polypeptide according to any one of claims 1-4, further comprising a CH1 region, in particular further comprising a hinge, a CH2 region, and a CH3 region.

6. A CD3 binding domain comprising the polypeptide according to any one of claims 1-5.

7. The CD3 binding domain according to claim 6, wherein the CD3 binding domain further comprises a polypeptide comprising a light chain variable region.

8. A group of antigen-binding proteins that bind human CD3, wherein each antigen-binding protein within the group comprises a heavy chain variable region and light chain variable region, the heavy chain variable region comprising a HCDR3 having at least 70% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4.

9. The CD3 binding domain according to claim 7 or the group of antigen-binding proteins according to claim 8, wherein the light chain variable region comprises:

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 5;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 41;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 42;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 43 or 68;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 45 or 69;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 49;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 50;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 52;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 53;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 56;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 57;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 58 or 70;

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 59 or 71; or

- the light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3), of a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 64 or 72,

or a variant thereof wherein each of the LCDRs may contain one, two, or at most three amino acid variations.

10. The CD3 binding domain or the group of antigen-binding proteins according to claim 9, wherein the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 5; 41; 42; 43 or 68; 45 or 69; 49; 50; 52; 53; 56; 57; 58 or 70; 59 or 71; or 64 or 72, or having at least 80%, or at least 85%, or at least 90%, or at least 95%, sequence identity thereto.

11. The CD3 binding domain or the group of antigen-binding proteins according to claim 9 or 10, further comprising a CL region.

12. A binding moiety comprising a polypeptide as claimed in any one of claims 1-3, or a CD3 binding domain according to claim 6 or 7, in particular wherein the binding moiety is a multispecific binding moiety, in particular a bispecific or trispecific antibody.

13. A pharmaceutical composition comprising an effective amount of a polypeptide according to any one of claims 1-5, or a CD3 binding domain according to claim 6 or 7, or a binding moiety according to claim 12, and a pharmaceutically acceptable carrier.

14. A polypeptide according to any one of claims 1-5, or a CD3 binding domain according to claim 6 or 7, or a binding moiety according to claim 12, or a pharmaceutical composition according to claim 13, for use in therapy, in particular for use in the treatment of cancer.

15. Use of an effective amount of a polypeptide according to any one of claims 1-5, or a CD3 binding domain according to claim 6 or 7, or a binding moiety according to claim 12, or a pharmaceutical composition according to claim 13 in the manufacture of a medicament for treating a disease, in particular for treating cancer.

16. A nucleic acid comprising a sequence encoding the polypeptide according to any one of claims 1-5.

17. A vector comprising a nucleic acid according to claim 16, in particular wherein the vector further comprises at least one nucleic acid sequence encoding a light chain variable region, and preferably a CL region, and in particular wherein the light chain variable region is a light chain variable region as defined in claim 9.

18. A cell comprising a nucleic acid according to claim 16, in particular wherein the cell further comprises at least one nucleic acid comprising a sequence that encodes a light chain variable region, and preferably a CL region, and in particular, wherein the light chain variable region is a light chain variable region as defined in claim 9.

19. A cell producing a polypeptide according to any one of claims 1-5, or a CD3 binding domain according to claim 6 or 7, or a binding moiety according to claim 12. 20. The cell according to claim 19, wherein the cell is a recombinant cell comprising the vector according to claim 17.